Industry

Remigromig meets endpoint in phase 2b/3 DME trial

Healio Optometry3d ago1 min read

Editor’s note: This is a developing news story. Please check back soon for updates.Remigromig was noninferior to ranibizumab at 52 weeks in patients with diabetic macular edema, according to a press release from Merck.The investigational therapy was well tolerated, but there were “higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations due to adverse events” in those who received remigromig compared with ranibizumab, according to the release.Researchers assessed the safety and efficacy of remigromig, also known as MK-3000 and formerly known as

Read full article on Healio Optometry

AI Summary

Quick Take

Merck’s investigational therapy remigromig (MK-3000) met its primary endpoint of noninferiority to ranibizumab at 52 weeks in a Phase 2b/3 trial for diabetic macular edema. While the drug achieved comparable efficacy in vision outcomes, the trial revealed concerning safety signals, including higher rates of proliferative diabetic retinopathy and vitreous hemorrhage compared to the control group.

Why It Matters

In the competitive landscape of DME treatments, noninferiority to a standard-of-care anti-VEGF like ranibizumab is a necessary baseline, but safety remains the ultimate differentiator. The reported increase in proliferative disease and vitreous hemorrhage is a significant clinical hurdle that may overshadow the efficacy results. Retina specialists will need to see more granular data to understand if these adverse events are related to the drug's mechanism or trial design, as any new therapy must prove it doesn't inadvertently accelerate retinopathy progression while treating edema.

Key Findings

Remigromig demonstrated noninferiority to ranibizumab in patients with diabetic macular edema over a 52-week period.
The study reported higher rates of proliferative diabetic retinopathy (PDR) in patients receiving remigromig compared to those receiving ranibizumab.
Incidences of vitreous hemorrhage were more frequent in the remigromig treatment arm.
The investigational therapy was associated with a higher rate of treatment discontinuations due to adverse events than the ranibizumab arm.
Despite the specific safety concerns, Merck characterized the investigational therapy as generally well tolerated.

Study Snapshot

Design

Phase 2b/3 clinical trial

Population

Patients with diabetic macular edema (DME)

Practice Implications

Clinicians should maintain a cautious outlook on remigromig until full safety data is published, particularly regarding its impact on the progression of diabetic retinopathy. If the higher rates of vitreous hemorrhage and PDR are confirmed, this agent may require more intensive monitoring or be contraindicated for patients with high-risk non-proliferative diabetic retinopathy.

Who's Affected

Retina SpecialistsOphthalmologistsClinical Researchers

What's Next

Merck is expected to release more comprehensive data from the Phase 2b/3 trial at future medical meetings. The industry will be watching for a deeper analysis of the adverse events to see if remigromig remains a viable candidate for regulatory submission.

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.